Skip to main content
SpringerLink
Log in

Hereditary Breast Cancer: an Overview

  • Conference paper
Progress in Anti-Cancer Chemotherapy

Part of the book series: Progress in Anti-Cancer Chemotherapy ((ANTI-CANCER,volume 3))

  • 61 Accesses

Abstract

It is estimated that hereditary breast cancer accounts for up to 10% of all cases of breast cancer [1]. Thus, of the 180,000 cases of breast cancer diagnosed yearly, up to 18,000 may be due to an inherited predisposition to this disease. To date, several genes have been identified that account for different hereditary breast cancer syndromes. BRCA1 and BRCA2 mutations are thought to account for the majority of inherited breast cancer. Although less frequent, hereditary breast cancer may be a feature of Li-Fraumeni and Cowden syndrome and may also occur in Ataxia Telangiectasia heterozygotes. In addition, it is likely that other rare, as yet unidentified, genes exist.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77: 2318–2324

    Article  PubMed  CAS  Google Scholar 

  2. Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71

    Article  PubMed  CAS  Google Scholar 

  3. Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792

    Article  PubMed  CAS  Google Scholar 

  4. Holt JT, Thompson ME, Szabo C et al (1996) Growth retardation and tumor inhibition by BRCA1. Nature Genet 12:298–302

    Article  PubMed  CAS  Google Scholar 

  5. Sharan SK, Morimatsu M, Albrecht U et al (1997) Embryonic lethality and radiation hypersensitivity mediated by rad51 in mice lacking BRCA2. Nature 386:804–810

    Article  PubMed  CAS  Google Scholar 

  6. Scully R, Chen J, Plug A et al (1997) Association of BRCA1 with rad51 in mitotic and meiotic cells. Cell 88:265–275

    Article  PubMed  CAS  Google Scholar 

  7. Breast Cancer Information Core (1998) http://www.nhgri.nih.gov/intramural_research/Lab_transfer/Bic/intramural_research/Lab_transfer/Bic

  8. Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Eng J Med 336:1401–1408

    Article  CAS  Google Scholar 

  9. Easton DP, Ford D, Bishop T and the Breast Cancer Linkage Consortium (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 56:265–271

    Google Scholar 

  10. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE and the Breast Cancer Linkage Consortium (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343: 692–695

    Article  Google Scholar 

  11. Serova OM, Mazoyer S, Puget N et al (1997) Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast-cancer susceptibility genes? Am J Hum Genet 60:486–495

    PubMed  CAS  Google Scholar 

  12. Struewing JP, Brody LC, Erdos MR et al (1995) Detection of eight BRCAl mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 57:1–7

    PubMed  CAS  Google Scholar 

  13. Easton DF, Steele L, Fields P et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13ql2–13. Am J Hum Genet 61:120–128

    Article  PubMed  CAS  Google Scholar 

  14. Friedman LS, Gayther SA, Kurosaki T et al (1997) Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60:313–319

    PubMed  CAS  Google Scholar 

  15. Phelan CM, Lancaster JM, Tonin P et al (1997) Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nature Genet 13:120–122

    Article  Google Scholar 

  16. Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCAl and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689

    Article  PubMed  CAS  Google Scholar 

  17. Seynaeve C, v.d. Bosch LMC, Brekelmans LC, et al. Local recurrence following lumpectomy and irradiation in familial and hereditary vs sporadic breast cancer patients. Proc Am Soc Clin Oncol 1998; 17: 457 (abstract)

    Google Scholar 

  18. Hayes DF, Kaplan W (1996) Evaluation of the patient after primary therapy In: Harris JR, Lippman ME, Morrow M & Hellman S (eds) Diseases of the Breast. Philadelphia, Lippincott-Raven, pp 629–647

    Google Scholar 

  19. Landis SH, Murray T, Bolden S, Wingo PA (1998) Cancer Statistics, 1998. CA Cancer J Clin 48:6–29

    Article  PubMed  CAS  Google Scholar 

  20. Tonin P, Weber B, Offit K et al (1996) Frequency of recurrent BRCAl and BRCA2 mutations in Ashkenazi Jewish breast cancer famihes. Nature Med 2:1179–1183

    Article  PubMed  CAS  Google Scholar 

  21. Marcus JN, Page DL, Watson P, Narod SA, Lenoir GM, Lynch HT (1997) BRCAl and BRCA2 hereditary breast carcinoma phenotypes. Cancer 80:543–546

    Article  Google Scholar 

  22. Porter DE, Cohen BB, Wallace MR et al (1994) Breast cancer incidence, penetrance and survival in probable carriers of BRCAl gene mutation in families linked to BRCAl on ctomosome 17ql2–21. Br J Surg 81:1512–1515

    Article  PubMed  CAS  Google Scholar 

  23. Johannsson Ö, Ranstam J, Borg Ä, Olsson H (1998) Survival of BRCAl breast and ovarian cancer patients: A population based study from Southern Sweden. J Clin Oncol 16:397–404

    PubMed  CAS  Google Scholar 

  24. Narod, S, Goldgar D, Cannon-Albright L et al (1995) Risk modifiers in carriers of BRCAl mutations. Int J Cancer (Pred Oncol) 64:394–398

    Article  CAS  Google Scholar 

  25. Ursin G, Henderson BE, Haile RW et al (1997) Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/2 mutations more than other women? Cancer Res 57:3678–3681

    PubMed  CAS  Google Scholar 

  26. Narod S A, Risch H, Moslehi R et al (1998) Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med; 339: 424–8

    Article  PubMed  CAS  Google Scholar 

  27. Phelan CM, Rebbeck TR, Weber BL et al (1996) Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nature Genet 12:309–311

    Article  PubMed  CAS  Google Scholar 

  28. Malkin D (1993) The Li-Fraumeni syndrome. Principles and Practice of Oncology Updates 7:1–14

    Google Scholar 

  29. FitzGerald MG, Bean JM, Hegde SR et al (1997) Heterozygous ATM mutations do not contribute to early onset breast cancer. Nature Genet 15:307–310

    Article  CAS  Google Scholar 

  30. Savitsky K, Bar-Shira A, Gilad S et al (1995) A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268:1749–1753

    Article  PubMed  CAS  Google Scholar 

  31. Athma P, Rappaport R, Swift M (1996) Molecular genotyping shows ataxia telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92:130–134

    Article  PubMed  CAS  Google Scholar 

  32. Starink TM, Van der Veen JPW, Arwert F et al (1986) The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 29:222–233

    Article  PubMed  CAS  Google Scholar 

  33. Nelen MR, Padberg GW, Peeters EAJ et al (1996) Localization of the gene for Cowden disease to chromosome 10q22–23. Nature Genet 13:114–116

    Article  PubMed  CAS  Google Scholar 

  34. Szabo CI, King M-C (1997) Invited editorial: population genetics of BRCAl and BRCA2. Am J Hum Genet 60:1013–1020

    PubMed  CAS  Google Scholar 

  35. Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCAl and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457–1462

    PubMed  CAS  Google Scholar 

  36. FitzGerald MG, MacDonald DJ, Krainer M et al (1996) Germ-line BRCAl mutations in Jewish and non-Jewish women with early onset breast cancer. N Engl J Med 334:143–149

    Article  CAS  Google Scholar 

  37. Muto MG, Cramer DW, Tangir J, Berkowitz R, Mok S (1996) Frequency of the BRCAl 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res 56:1250–1252

    PubMed  CAS  Google Scholar 

  38. Abeliovich D, Kaduri L, Lerer I et al (1997) The founder mutations 185delAG and 5382insC in BRCAl and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi Jewish women. Am J Hum Genet 60:505–514

    PubMed  CAS  Google Scholar 

  39. Schubert EL, Mefford HC, Dann JL, Argonza RH, Hull J, King M-C (1997) BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer. Genetic Testing 1:41–46

    PubMed  CAS  Google Scholar 

  40. Parmigiani G, Berry DA, Aguilar O (1998) Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158

    Article  PubMed  CAS  Google Scholar 

  41. Frank TS, Manley SA, Olopade OI, etal. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998; 16: 2417–25

    PubMed  CAS  Google Scholar 

  42. Matloff ET, Peshkin BN (1998) Complexities in cancer genetic counseling: breast and ovarian cancer. Principles and Practice of Oncology Updates 12 (1): 1–11

    Google Scholar 

  43. Croyle RT, Smith KR, Botkin JR, Baty B, Nash J (1997) Psychological responses to BRCAl mutation testing: preliminary findings. Health Psychol 16:63–72

    Article  PubMed  CAS  Google Scholar 

  44. Lerman C, Narod S, Schulman K et al (1996) BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA 275:1885–1892

    Article  PubMed  CAS  Google Scholar 

  45. Burke W, Daly M, Garber J et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCAl and BRCA2. JAMA 277:997–1003

    Article  PubMed  CAS  Google Scholar 

  46. Hartmann L, Jenkins R, Schaid D, Yang P (1997) Prophylactic mastectomy (PM): preliminary retrospective cohort analysis. Proc Am Assoc Cancer Res 38:1123 (Abstract)

    Google Scholar 

  47. Ziegler LD, Kroll SS (1991) Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 14:451–454

    PubMed  CAS  Google Scholar 

  48. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-I Study. J Natl. Cancer Inst 1998; 90: 1371–88

    Article  PubMed  CAS  Google Scholar 

  49. NIH Consensus Development Panel on Ovarian Cancer (1995) Ovarian cancer: screening, treatment and follow-up. JAMA 273:491–497

    Article  Google Scholar 

  50. Piver MS, Jishi MF, Tsukada Y, Nava G (1993) Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. Cancer 71:2751–2755

    Article  PubMed  CAS  Google Scholar 

  51. Struewing JF, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA (1995) Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 17:33–35

    PubMed  Google Scholar 

  52. Vessey MP, Painter R (1995) Endometrial and ovarian cancer and oral contraceptives. Br J Cancer 71:1340–1342

    Article  PubMed  CAS  Google Scholar 

  53. Rosenberg L, Palmer JR, Zauber AG et al (1994) A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139:654–661

    PubMed  CAS  Google Scholar 

  54. Brinton LA, Daling JR, Liff JM et al (1995) Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 87:827–835

    Article  PubMed  CAS  Google Scholar 

  55. Rosenberg L, Palmer JR, Rao S et al (1996) Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol 143:25–37

    Article  PubMed  CAS  Google Scholar 

  56. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713–1727

    Article  Google Scholar 

  57. Grady D, Rubin SM, Petitti, DB et al (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 117:1016–1037

    PubMed  CAS  Google Scholar 

  58. Colditz GA, Hankinson SE, Hunter DJ et al (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Eng J Med 332:1589–1593

    Article  CAS  Google Scholar 

  59. Statement of the American Society of Clinical Oncology (1996) genetic testing for cancer susceptibility. J Clin Oncol 14:1730–1736

    Google Scholar 

  60. McKinnon WC, Baty BJ, Bennett RL et al (1997) Predisposition genetic testing for late-onset disorders in adults: a position paper of the National Society of Genetic Counselors. JAMA 278:1217–1220

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. C. J. D. Isaacs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. N. Peshkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. MD Anderson Cencer Center, Cepartment of Breast Medical Oncology, University of Texas, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA

    Gabriel N. Hortobagyi

  2. Pitié-Salpétrière Hospital, SOMPS, 47, bd de l’Hôpital, 75651, Paris Cedex 13, France

    David Khayat

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag France

About this paper

Cite this paper

Isaacs, C.J.D., Peshkin, B.N. (1999). Hereditary Breast Cancer: an Overview. In: Hortobagyi, G.N., Khayat, D. (eds) Progress in Anti-Cancer Chemotherapy. Progress in Anti-Cancer Chemotherapy, vol 3. Springer, Paris. https://doi.org/10.1007/978-2-8178-0918-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0918-2_4

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-59666-7

  • Online ISBN: 978-2-8178-0918-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation